Bristol-Myers' win in U.S. patent case against Gilead boosted to $1.2 billion
A federal judge increased to $1.2 billion the damages that Gilead Sciences Inc must pay to Bristol-Myers Squibb Co in a patent infringement case regarding technology for treating cancer.
No comments:
Post a Comment